Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis
Authors' conclusion
Daily colchicine is the first-line therapy used in chronic CPP crystal inflammatory arthritis, which is considered efficient in a third to half of cases. Second-line treatments include methotrexate and tocilizumab, which have higher retention than anakinra.
Study context
- Population
- Patients with persistent inflammatory and/or recurrent acute CPP crystal arthritis, seven expert European centrestreatments in 129 patients
- Participants
- 194 patients
- Exposure
- Colchicine, methotrexate, anakinra and tocilizumab for chronic CPP crystal inflammatory arthritis
- Colchicinen = 86
- Methotrexaten = 36
- Anakinran = 27
- Tocilizumabn = 25
- Outcome
- On-drug treatment retention
- Follow-up
- 24 months
Methodological detailsmulticentre (seven European centres), chart review
- Multicentre (seven European centres)
- Chart review
Main finding
As reported in the abstract
On-drug retention
Tocilizumab vs Anakinra: P < 0.05 · Colchicine vs Methotrexate: P = 0.10
Observational data: associations, not effects.
Further findings
Efficacy outcomes · throughout follow-up
- Did not differ significantly between treatments
Safety
Discontinuations due to AEs (share of discontinuations)
- Discontinuations due to AEs (share of discontinuations): colchicine AE discontinuations: 100% diarrhoea
Original publication
Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis. Rheumatology (Oxford). Published 22 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →